Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study in Patients With Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Adriamycin (Doxorubicin), Taxotere (Docetaxel), and Cyclophosphamide (ATC)

NCT00003352 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT00003352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study in Patients With Metastatic or Locally Advanced Breast Cancer to Evaluate the Worth of the Combination of Adriamycin (Doxorubicin), Taxotere (Docetaxel), and Cyclophosphamide (ATC)
Lead sponsor
NSABP Foundation Inc
Phase
Phase 2
Overall status
Completed
Start date
June 30, 1998
Completion date
December 31, 2002
Enrollment
89 (actual)
Sites
166

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer